Alfresa Holdings Corporation (ALFRY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alfresa Holdings Corporation (ALFRY) trades at $13.80 with AI Score 49/100 (Grade C). Alfresa Holdings Corporation operates in the healthcare sector, focusing on pharmaceutical distribution, manufacturing, and medical-related services. Market cap: $2.51B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ALFRY: ALFRY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALFRY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALFRY: the 1 perspectives are evenly split.
How is this calculated? →Alfresa Holdings Corporation (ALFRY) Healthcare & Pipeline Overview
Alfresa Holdings Corporation, a Japanese healthcare conglomerate, manufactures, wholesales, and distributes pharmaceuticals, diagnostic reagents, and medical devices. With a focus on ethical pharmaceuticals and self-medication products, the company serves hospitals, clinics, and pharmacies in Japan and internationally, maintaining a stable position in the medical distribution landscape.
What Is the Investment Thesis for ALFRY?
Alfresa Holdings Corporation presents a stable investment profile within the healthcare distribution sector. The company's diversified revenue streams, spanning ethical pharmaceuticals, self-medication products, and manufacturing, provide resilience against market fluctuations. With a P/E ratio of 9.4 and a dividend yield of 2.76% as of 2026-03-16, Alfresa offers a blend of value and income potential. The company's low beta of -0.16 suggests a lower sensitivity to market volatility compared to its peers. Growth catalysts include expanding its self-medication product lines and penetrating new international markets. Potential risks include regulatory changes in the pharmaceutical industry and increased competition from other distributors.
Based on FMP financials and quantitative analysis
ALFRY Key Highlights
- Market capitalization of $2.51B indicates a substantial presence in the healthcare sector.
- P/E ratio of 9.4 suggests a reasonable valuation compared to earnings.
- Dividend yield of 2.76% provides a steady income stream for investors.
- Gross margin of 7.1% reflects the company's ability to manage its cost of goods sold.
- Profit margin of 1.1% indicates areas for potential improvement in operational efficiency.
Who Are ALFRY's Competitors?
ALFRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHSYF China Medical System Holdings Limited | $1.57 | -0.00% | $3.80B | 53 |
| DMPHF Dermapharm Holding SE | $53.00 | +0.00% | $2.63B | 50 |
| HAWPF Haw Par Corporation Limited | $12.00 | +0.00% | $2.66B | 49 |
| HTSUF Hisamitsu Pharmaceutical Co., Inc. | $29.00 | +0.00% | $2.04B | 48 |
| MAHLY MediPal Holdings Corporation | $15.75 | -3.26% | $3.22B | 48 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALFRY's Key Strengths?
- Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.
- Established distribution network in Japan.
- Strong relationships with key customers, including hospitals and pharmacies.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
What Are ALFRY's Weaknesses?
- Relatively low profit margin compared to industry peers.
- Dependence on the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence compared to global competitors.
What Could Drive ALFRY Stock Higher?
- Expansion of self-medication product lines to meet growing consumer demand for OTC drugs and health supplements.
- Strategic partnerships to enhance distribution network and market reach in key regions.
- Potential regulatory approvals for new pharmaceutical products, expanding the company's product portfolio.
- Investment in digital distribution channels to capitalize on the growth of e-pharmacy market.
- Development of value-added services to enhance customer loyalty and generate recurring revenue.
What Are the Key Risks for ALFRY?
- Increased competition from other pharmaceutical distributors, leading to pricing pressures.
- Changes in government regulations and healthcare policies, affecting reimbursement rates and market access.
- Economic downturns affecting healthcare spending and consumer demand for pharmaceuticals.
- Currency fluctuations between the U.S. dollar and the Japanese yen, impacting the value of the ADR.
- Product liability claims or recalls, damaging the company's reputation and financial performance.
What Are the Growth Opportunities for ALFRY?
- Expanding Self-Medication Product Lines: Alfresa can capitalize on the growing demand for over-the-counter drugs and health supplements. The global self-medication market is projected to reach $200 billion by 2028. By introducing innovative products and expanding its distribution network, Alfresa can increase its market share in this segment. Timeline: Ongoing.
- Penetrating New International Markets: Alfresa has the opportunity to expand its presence in emerging markets with growing healthcare needs. The Asia-Pacific region, in particular, offers significant growth potential. By establishing partnerships and adapting its product offerings to local market demands, Alfresa can diversify its revenue streams. Timeline: 2-3 years.
- Enhancing Contract Manufacturing Services: Alfresa can leverage its manufacturing capabilities to offer contract manufacturing services to other pharmaceutical companies. The global pharmaceutical contract manufacturing market is expected to reach $150 billion by 2027. By investing in advanced manufacturing technologies and expanding its capacity, Alfresa can attract new clients and generate additional revenue. Timeline: Ongoing.
- Strengthening Digital Distribution Channels: Alfresa can enhance its online presence and develop digital distribution channels to reach a wider customer base. The e-pharmacy market is experiencing rapid growth, driven by increasing internet penetration and changing consumer preferences. By investing in e-commerce platforms and digital marketing strategies, Alfresa can capture a share of this growing market. Timeline: 1-2 years.
- Developing Value-Added Services: Alfresa can differentiate itself from competitors by offering value-added services to its customers, such as inventory management, supply chain optimization, and data analytics. These services can help hospitals, clinics, and pharmacies improve their operational efficiency and reduce costs. By providing customized solutions and building strong customer relationships, Alfresa can enhance customer loyalty and generate recurring revenue. Timeline: Ongoing.
What Opportunities Does ALFRY Have?
- Expanding self-medication product lines to capitalize on growing consumer demand.
- Penetrating new international markets, particularly in Asia-Pacific.
- Enhancing contract manufacturing services to generate additional revenue.
- Strengthening digital distribution channels to reach a wider customer base.
What Threats Does ALFRY Face?
- Increased competition from other pharmaceutical distributors.
- Pricing pressures from generic drugs.
- Changes in government regulations and healthcare policies.
- Economic downturns affecting healthcare spending.
What Are ALFRY's Competitive Advantages?
- Established distribution network in Japan.
- Diversified product portfolio spanning pharmaceuticals, diagnostics, and medical devices.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
- Strong relationships with hospitals, clinics, and pharmacies.
What Does ALFRY Do?
Incorporated in 2003 and based in Tokyo, Japan, Alfresa Holdings Corporation has established itself as a key player in the healthcare sector. The company operates through its subsidiaries, engaging in the manufacture, wholesale, marketing, and import/export of a diverse range of healthcare products. These include pharmaceuticals, diagnostic reagents, and medical devices/equipment. Alfresa's operations are segmented into ethical pharmaceuticals wholesaling, self-medication products wholesaling, and manufacturing. The ethical pharmaceuticals division supplies hospitals, clinics, and dispensing pharmacies with essential products. The self-medication division caters to drug stores and pharmacies, offering over-the-counter drugs, health foods, and supplements. Alfresa also manufactures active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, providing contract manufacturing services. The company's medical-related business encompasses dispensing pharmacies and other healthcare activities, further solidifying its presence in the healthcare value chain. Alfresa's international reach extends its market presence beyond Japan, contributing to its revenue streams and overall growth.
What Products and Services Does ALFRY Offer?
- Wholesales ethical pharmaceuticals to hospitals, clinics, and dispensing pharmacies.
- Distributes self-medication products, including OTC drugs and health supplements, to drug stores and pharmacies.
- Manufactures active pharmaceutical ingredients and pharmaceuticals.
- Produces diagnostic reagents and medical devices.
- Offers contract manufacturing services for pharmaceuticals.
- Operates dispensing pharmacies.
How Does ALFRY Make Money?
- Revenue from wholesale distribution of pharmaceuticals and medical products.
- Income from manufacturing and sales of active pharmaceutical ingredients and finished drugs.
- Fees from contract manufacturing services.
- Revenue generated from operation of dispensing pharmacies.
What Industry Does ALFRY Operate In?
Alfresa Holdings Corporation operates within the medical distribution industry, a sector characterized by steady growth driven by aging populations and increasing healthcare expenditure. The industry is competitive, with players like CHSYF, DMPHF, HAWPF, HTSUF, and MAHLY vying for market share. Trends include consolidation among distributors and increased focus on supply chain efficiency. Alfresa's diversified product portfolio and established distribution network position it favorably within this landscape.
Who Are ALFRY's Key Customers?
- Hospitals and clinics.
- Dispensing pharmacies.
- Drug stores.
- Other pharmaceutical companies (for contract manufacturing).
FY2026 estForward Outlook
Wall Street analysts project Alfresa Holdings Corporation revenue of about $3.10T for fiscal 2026, with EPS near $0.00. The estimate reflects 3 contributing analysts.
F-Score 5/9Financial Health
Alfresa Holdings Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.98 places it in the grey zone, a middle ground that warrants monitoring.
ROE 8%Key Financial Metrics
Return on equity for Alfresa Holdings Corporation stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.8%, showing how much profit it generates from its asset base. ALFRY trades at a trailing price-to-earnings ratio of 9.42, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.6%, the inverse of the P/E and a quick read on earnings relative to price.
Alfresa Holdings Corporation (ALFRY) Valuation Context
Valued at $2.51B, ALFRY is classified as a mid-cap stock. Relative to its peer group, ALFRY's quantitative score of 49/100 is roughly in line with the peer average of 50/100.
ALFRY Revenue & Earnings Trend
In Q1 2026, ALFRY generated $754.59B in top-line revenue, marking a sequential decrease of 11.1%. The company recorded net income of $9.94B, with diluted EPS of $54.33. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ALFRY averaged $58.09 in diluted EPS.
Company Profile
Alfresa Holdings Corporation operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Ryuji Arakawa. ALFRY has traded publicly since 2018.
ALFRY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Alfresa's recent insider buying indicates strong confidence from leadership, suggesting they believe in the company's future growth.
- Community sentiment has turned positive recently, with discussions highlighting Alfresa's expanding product lines and market reach.
- Recent partnerships in the pharmaceutical sector have bolstered market perception, positioning Alfresa as a key player in healthcare.
- The overall trend in healthcare spending is rising, and Alfresa is well-placed to capitalize on this growing demand.
Bear Case
- Despite recent positive sentiment, there are concerns about regulatory challenges in the pharmaceutical industry that could impact operations.
- Some community members have raised alarms about potential supply chain disruptions affecting product availability and revenue.
- Market perception remains cautious due to global economic uncertainties, which could affect Alfresa's growth trajectory.
- There’s a notable bearish sentiment surrounding potential competition from larger pharmaceutical companies that could overshadow Alfresa's market presence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $754.59B | $9.94B | $54.33 |
| Q4 2025 | $848.37B | $20.83B | $114.50 |
| Q3 2025 | $785.10B | $6.63B | $36.00 |
| Q2 2025 | $758.12B | $5.00B | $27.52 |
Based on FMP financials and quantitative analysis
ALFRY Latest News
No recent news available for ALFRY.
ALFRY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALFRY.
Price Targets
Wall Street price target analysis for ALFRY.
ALFRY MoonshotScore
What does this score mean?
The MoonshotScore rates ALFRY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ryuji Arakawa
Unknown
Information regarding Ryuji Arakawa's specific background and career history is not available in the provided data. However, as the managing leader of Alfresa Holdings Corporation's 12,517 employees, Arakawa likely possesses extensive experience in the pharmaceutical or healthcare distribution industry. Further research would be needed to ascertain specific details about his education, previous roles, and credentials.
Track Record: Due to the limited information available, Ryuji Arakawa's specific achievements and strategic decisions as CEO of Alfresa Holdings Corporation cannot be detailed. Evaluating his track record would require access to company performance data, strategic initiatives, and key milestones achieved under his leadership.
Alfresa Holdings Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. ALFRY is an ADR representing shares of Alfresa Holdings Corporation, allowing U.S. investors to invest in the Japanese company without directly dealing with foreign exchanges. The ADR is denominated in U.S. dollars, simplifying trading and investment for U.S. investors.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ALFR
ALFRY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to be SEC reporting.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in ALFRY.
- Low trading volume and wide bid-ask spreads can lead to price volatility and illiquidity.
- Lack of regulatory oversight increases the risk of fraud or manipulation.
- Potential for delisting or suspension of trading.
- Difficulty obtaining accurate and timely information about the company.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Understand the OTC market and its associated risks.
- The company is an established player in the healthcare sector.
- Alfresa Holdings Corporation is based in Japan, a country with strong corporate governance standards.
- The company has a long operating history.
- ALFRY is an ADR, suggesting some level of scrutiny and compliance.
- The company has a market capitalization of $2.51B, indicating a substantial business.
ALFRY Healthcare Stock FAQ
What does Alfresa Holdings Corporation do?
Alfresa Holdings Corporation is a comprehensive healthcare company involved in the manufacture, wholesale, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Operating primarily in Japan and internationally, Alfresa serves a diverse customer base, including hospitals, clinics, dispensing pharmacies, and drug stores. The company's business model encompasses ethical pharmaceuticals wholesaling, self-medication products wholesaling, manufacturing of active pharmaceutical ingredients, and operation of dispensing pharmacies, positioning it as a key player in the healthcare supply chain.
What are the main risks for ALFRY?
Alfresa Holdings Corporation faces several risks inherent to the healthcare distribution industry. These include increased competition from other pharmaceutical distributors, pricing pressures from generic drugs, and changes in government regulations and healthcare policies. Additionally, the company is exposed to currency fluctuations between the U.S. dollar and the Japanese yen, as well as potential product liability claims or recalls. Investors should carefully consider these risks before investing in ALFRY.
What are the key factors to evaluate for ALFRY?
Alfresa Holdings Corporation (ALFRY) holds an AI score of 49/100 (low). P/E: 9.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ALFRY data refresh on this page?
ALFRY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALFRY's recent stock price performance?
Alfresa Holdings Corporation (ALFRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified revenue streams across wholesale, manufacturing, and pharmacy operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALFRY overvalued or undervalued right now?
Alfresa Holdings Corporation (ALFRY) trades at 9.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALFRY?
Before investing in Alfresa Holdings Corporation (ALFRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ALFRY to a portfolio?
Key strength of Alfresa Holdings Corporation (ALFRY): Diversified revenue streams across wholesale, manufacturing, and pharmacy operations. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- Analyst consensus and detailed CEO background information are limited.
- OTC market data may be less reliable than exchange-listed data.